Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan (PSP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding equity transactions rather than a financial results report.
Material Changes
The filing details an increase in share interests for specific individuals due to the reinvestment of dividends on previously vested PSP awards. The following shares vested on May 3, 2012:
- Mr P C Thomson: 5 shares
- Dr P J T Vallance: 185 shares
- Mrs V A Whyte: 5 shares
- Mr C Weber: 43 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rules 3.1.4R(1)(a).
Investor Verification Points
- Confirm the total number of vested shares for each named director.
- Verify the date of the original PSP award vesting (February 17, 2012) referenced in the dividend reinvestment.
- Check subsequent filings for broader financial performance data not included in this transaction notice.